PET/SPECT imaging agents for neurodegenerative diseases
Open accessAbstract
Amyvid/PET imaging of a living brain detects β-amyloid plaque deposition, a risk factor for developing Alzheimer's disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Diagnosis of neurodegenerative diseases is usually based on subjective cognitive tests in combination with neuroimaging, but the current techniques are not able to successfully diagnose these diseases in their earlier stages, when the pathology is already present but does not cause symptoms yet.
“Diagnosis of neurodegenerative diseases is usually based on subjective cognitive tests in combination with neuroimaging [131–133], but the current techniques are not able to successfully diagnose these diseases in their earlier stages, when the pathology is already present but does not cause symptoms yet.”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [133]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works
Hamacher, K., Coenen, H. H., & Stöcklin, G. (1986) · PubMed · Cited by 1,368 · see citing works
Ametamey, S. M., Honer, M., & Schubiger, P. A. (2008) · Chemical Reviews · doi:10.1021/cr0782426 · Cited by 1,280 · see citing works
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117 · see citing works
Weissleder, R. (2006) · Science · doi:10.1126/science.1125949 · Cited by 1,107 · see citing works
PET versus SPECT: strengths, limitations and challenges
Rahmim, A., & Zaidi, H. (2008) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3282f3a515 · Cited by 843 · see citing works
Vandenberghe, R. R., Laere, K. V., Ivanoiu, A., Salmon, É., Bastin, C., Triau, E., Hasselbalch, S. G., Law, I. G., Andersen, A., Kørner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 649 · see citing works
Potential Technetium Small Molecule Radiopharmaceuticals
Jurisson, S. S., & Lydon, J. D. (1999) · Chemical Reviews · doi:10.1021/cr980435t · Cited by 593 · see citing works
The use of PET in Alzheimer disease
Nordberg, A. K., Rinne, J. O., Kadir, A., & Långström, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.217 · Cited by 451 · see citing works
Eustance, C. N. P. (2004) · Radiography · doi:10.1016/j.radi.2004.01.016 · Cited by 428 · see citing works
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
Frey, K. A., Koeppe, R. A., Kilbourn, M. R., Borght, T. M. V., Albin, R. L., Gilman, S., & Kuhl, D. E. (1996) · Annals of Neurology · doi:10.1002/ana.410400609 · Cited by 314 · see citing works
Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.007 · Cited by 270 · see citing works
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albin, R. L., Koeppe, R. A., Wernette, K., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254 · see citing works
Zhang, L., Villalobos, A., Beck, E. M., Bocan, T. M. A., Chappie, T. A., Chen, L. M., Grimwood, S., Heck, S. D., Helal, C. J., Hou, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400312y · Cited by 208 · see citing works
Kung, H. F., Choi, S., Qü, W., Zhang, W., & Skovronsky, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901039z · Cited by 200 · see citing works
Self-citationRowe, C. C., Pejoska, S., Mulligan, R. S., Jones, G. R., Chan, J. G., Svensson, S., Cselényi, Z., Masters, C. L., & Villemagne, V. L. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114785 · Cited by 193 · see citing works
Novel Stilbenes as Probes for Amyloid Plaques
Kung, H. F., Lee, C., Zhuang, Z., Kung, M., Hou, C., & Plöessl, K. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0167147 · Cited by 179 · see citing works
Self-citationBanerjee, S. R., Maresca, K. P., Francesconi, L. C., Valliant, J. F., Babich, J. W., & Zubieta, J. A. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2004.09.001 · Cited by 178 · see citing works
Development of Positron Emission Tomography β-Amyloid Plaque Imaging Agents
Mathis, C. A., Mason, N. S., Lopresti, B. J., & Klunk, W. E. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.07.001 · Cited by 176 · see citing works
Imaging biomarkers in Parkinson's disease.
Brooks, D., & Pavese, N. (2011) · Progress in neurobiology · doi:10.1016/j.pneurobio.2011.08.009 · Cited by 163 · see citing works
[ 99m Tc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease
Siderowf, A. D., Newberg, A. B., Chou, K. L., Lloyd, M., Colcher, A., Hurtig, H. I., Stern, M. B., Doty, R. L., Mozley, P. D., Wintering, N., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000161874.52302.5d · Cited by 163 · see citing works
Okamura, N., Villemagne, V. L., Drago, J., Pejoska, S., Dhamija, R. K., Mulligan, R. S., Ellis, J. R., Ackermann, U., O'Keefe, G. J., Jones, G. R., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070094 · Cited by 136 · see citing works
Self-citationTayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119 · see citing works
The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing
Kung, H. F. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300058m · Cited by 109 · see citing works
Self-citationVillemagne, V. L., Furumoto, S., Fodero‐Tavoletti, M. T., Harada, R., Mulligan, R. S., Kudo, Y., Masters, C. L., Yanai, K., Cc, R., & Okamura, N. (2012) · Future Neurology · doi:10.2217/fnl.12.34 · Cited by 98 · see citing works
[3H]Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain
Scherman, D., Raisman‐Vozari, R., Ploska, A., & Agid, Y. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb10583.x · Cited by 85 · see citing works
Kung, M., Hou, C., Goswami, R., Ponde, D. E., Kilbourn, M. R., & Kung, H. F. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.12.005 · Cited by 78 · see citing works
Self-citationAlzheimer’s drugs take a new tack
Callaway, E. (2012) · Nature · doi:10.1038/489013a · Cited by 77 · see citing works
Gambhir, S. S. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.053751 · Cited by 77 · see citing works
A shielded synthesis system for production of 2-deoxy-2-[18F]fluoro-D-glucose.
Fowler, J. S., MacGregor, R. R., Wolf, A. P., Farrell, A. A., Karlstrom, K. I., & Ruth, T. J. (1981) · PubMed · Cited by 71 · see citing works
Trends in Nuclear Medicine in Developing Countries
Dondi, M., Kashyap, R., Páez, D., Pascual, T. N. B., Zaknun, J. J., Bastos, F. M., & Pynda, Y. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089193 · Cited by 67 · see citing works
The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study.
Seifert, K. D., & Wiener, J. I. (2013) · Europe PMC (PubMed Central) · Cited by 66 · see citing works
Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson’s disease?
Tatsch, K. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0814-5 · Cited by 64 · see citing works
Translational PET imaging research
Hargreaves, R. J., & Rabiner, E. A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.017 · Cited by 61 · see citing works
Kilbourn, M. R., & Frey, K. A. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00252-x · Cited by 44 · see citing works
Villemagne, V. L. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.142 · Cited by 43 · see citing works
Zeng, F., & Goodman, M. M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313080004 · Cited by 38 · see citing works
Seibyl, J. P., Russell, D., Jennings, D. L., & MAREK, K. L. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.06.003 · Cited by 28 · see citing works
Seibyl, J. P. (2008) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.03.001 · Cited by 25 · see citing works
Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson’s Disease
Neal, K. L., Shakerdge, N. B., Hou, S. S., Klunk, W. E., Mathis, C. A., Nesterov, E. E., Swager, T. M., McLean, P. J., & Bacskai, B. J. (2013) · Molecular Imaging and Biology · doi:10.1007/s11307-013-0634-y · Cited by 25 · see citing works
Molecular imaging as a guide for the treatment of central nervous system disorders
Kim, E., Howes, O., & Kapur, S. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.3/ekim · Cited by 23 · see citing works
Expanding the Scope of Fluorine Tags for PET Imaging
Zhu, L., Plöessl, K., & Kung, H. F. (2013) · Science · doi:10.1126/science.1245011 · Cited by 21 · see citing works
Self-citationA benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover.
Saner, A., & Pletscher, A. (1977) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31082-7 · Cited by 12 · see citing works
Frey, K. A. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0815-4 · Cited by 12 · see citing works
The Future of USP Monographs for PET Drugs
Schwarz, S. W., Norenberg, J. P., Berridge, M. S., Dragotakes, S. C., Hung, J. C., Link, J., Mason, N. S., Mattmuller, S., Nickel, R. A., Packard, A. B., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.115089 · Cited by 9 · see citing works
FDA cGMP requirements for PET drugs.
Norenberg, J. P., Schwarz, S. W., & VanBrocklin, H. F. (2011) · PubMed · Cited by 8 · see citing works
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Research works printed but not linked: 6
- [1]Norenberg JP Schwarz S VanBrocklin H J. Nucl. Med 2011 52 16N 21536923
- [10]Fowler JS MacGregor RR Wolf AP Farrell AA Karlstrom KI Ruth TJ J. Nucl. Med 1981 22 376 380 7205386
- [11]Hamacher K Coenen HH Stocklin G J. Nucl. Med 1986 27 235 238 3712040
- [12]M. H. S Ametamey M Schubiger PA Chem. Rev 2008 108 1501 1516 18426240
- [19]Frey KA Eur. J. Nucl. Med. Mol. Imaging 2002 29 715 717 11976814
- [20]Seifert KD Wiener JI Am J Neurodegener Dis 2013 2 29 34 23515233 PMC3601468
Cited by
Sorted by citations
Long-Lived Emissive Probes for Time-Resolved Photoluminescence Bioimaging and Biosensing
Zhang, K. Y., Yu, Q., Wei, H., Liu, S., Zhao, Q., & Huang, W. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00425 · Cited by 923 · see citing works
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750 · see citing works
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2018) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 378 · see citing works
Chemical Design of Activatable Photoacoustic Probes for Precise Biomedical Applications
Liu, Y., Teng, L., Yin, B., Meng, H., Yin, X., Huan, S., Song, G., & Zhang, X. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00875 · Cited by 249 · see citing works
Fluorescent probes for bioimaging of potential biomarkers in Parkinson's disease
Gao, L., Wang, W., Wang, X., Yang, F., Xie, L., Shen, J., Brimble, M. A., Xiao, Q., & Yao, S. Q. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00115e · Cited by 183 · see citing works
Recent advances in porphyrin-based MOFs for cancer therapy and diagnosis therapy
Wang, Z., Sun, Q., Liu, B., Kuang, Y., Gulzar, A., He, F., Gai, S., Yang, P., & Lin, J. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213945 · Cited by 171 · see citing works
Wang, P., Yu, L., Gong, J., Xiong, J., Zi, S., Xie, H., Zhang, F., Mao, Z., Liu, Z., & Kim, J. S. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202206894 · Cited by 163 · see citing works
Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer׳s disease
Tong, H., Lou, K., & Wang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.12.006 · Cited by 142 · see citing works
Fu, H., Cui, M., Zhao, L., Tu, P., Zhou, K., Dai, J., & Liu, B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00861 · Cited by 136 · see citing works
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · see citing works
Zheng, J., Wang, L., Lin, J., Xiao, J., & Liang, S. H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505446 · Cited by 129 · see citing works
Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys
Tao, Y., Vermilyea, S., Zammit, M. D., Lü, J., Olsen, M. E., Metzger, J. M., Yao, L., Chen, Y., Phillips, S., Holden, J. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01257-1 · Cited by 131 · see citing works
Transpathology: molecular imaging-based pathology
Tian, M., He, X., Jin, C., He, X., Wu, S., Zhou, R., Zhang, X., Zhang, K., Gu, W., Wang, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05234-1 · Cited by 124 · see citing works
An Activatable NIR‐II Fluorescent Reporter for In Vivo Imaging of Amyloid‐β Plaques
Miao, J., Miao, M., Jiang, Y., Zhao, M., Li, Q., Zhang, Y., An, Y., Pu, K., & Miao, Q. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202216351 · Cited by 118 · see citing works
Brain imaging and networks in restless legs syndrome
Rizzo, G., Li, X., Galantucci, S., Filippi, M., & Cho, Y. W. (2016) · Sleep Medicine · doi:10.1016/j.sleep.2016.07.018 · Cited by 107 · see citing works
Li, Y., Xu, D., Ho, S.-L., Li, H.-W., Yang, R., & Wong, M. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.047 · Cited by 102 · see citing works
Aβ plaque-selective NIR fluorescence probe to differentiate Alzheimer's disease from tauopathies
Rajasekhar, K., Narayanaswamy, N., Murugan, N. A., Viccaro, K., Lee, H., Shah, K., & Govindaraju, T. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.06.030 · Cited by 99 · see citing works
“While PET imaging is an important tool to image protein aggregates, it is expensive and hazardous to human health due to the use of radio-labeled nuclei (Zhu et al., 2014).”
BackgroundLanthanide porphyrinoids as molecular theranostics
Jin, G., Chau, C. V., Arambula, J. F., Gao, S. W., Sessler, J. L., & Zhang, J. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00275b · Cited by 97 · see citing works
Deep learning-based PET image denoising and reconstruction: a review
Hashimoto, F., Onishi, Y., Ote, K., Tashima, H., Reader, A. J., & Yamaya, T. (2024) · Radiological Physics and Technology · doi:10.1007/s12194-024-00780-3 · Cited by 103 · see citing works
“Thus, PET can observe tracer kinetics; therefore, it is used not only for cancer diagnosis [26, 27] and diagnosis of neurodegenerative diseases, such as Alzheimer's disease [28, 29], but for fundamental research, such as brain function [30, 31].”
MethodWu, Y., Jiang, J., Chen, L., Lu, J., Ge, J., Liu, F., Yu, J., Lin, W., Zuo, C., & Wang, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.26 · Cited by 91 · see citing works
“PET is commonly used for imaging to measure brain dysfunction (11).”
MethodBabiloni, C., Percio, C. D., Lizio, R., Noce, G., Lopez, S., Soricelli, A., Ferri, R., Nobili, F. M., Arnaldi, D., Famà, F., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.023 · Cited by 88 · see citing works
“PET or SPECT scan of dopamine transporter can also be used for the differential diagnosis between PDD and DLB on the one side and ADD on the other side (Zhu et al., 2014).”
BackgroundShellaiah, M., Simon, T., Srinivasadesikan, V., Lin, C.-M., Sun, K. W., Ko, F., Lin, M. C., & Lin, H. (2016) · Journal of Materials Chemistry C · doi:10.1039/c5tc03738g · Cited by 88 · see citing works
Metal-based imaging agents: progress towards interrogating neurodegenerative disease
Sedgwick, A. C., Brewster, J. T., Harvey, P., Iovan, D. A., Smith, G. S. T., He, X., Tian, H., Sessler, J. L., & James, T. D. (2020) · Chemical Society Reviews · doi:10.1039/c8cs00986d · Cited by 87 · see citing works
Li, X., Zhao, Y., Zhang, T., & Xing, D. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001240 · Cited by 81 · see citing works
Papapetropoulos, S., Pontius, A., Finger, E. C., Karrenbauer, V. D., Lynch, D. S., Brennan, M. J., Zappia, S., Koehler, W., Schöls, L. J., Hayer, S. N., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.788168 · Cited by 80 · see citing works
“These imaging techniques provide valuable information on clinical diagnosis, pathology, disease progression and patient care (57).”
BackgroundVolkow, N. D., Wang, G., Smith, L. A., Fowler, J. S., Telang, F., Logan, J., & Tomasi, D. G. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.07.035 · Cited by 75 · see citing works
“…findings contrast with those reported in Parkinson's Disease (PD) for which the degeneration of DA neurons and their terminals is associated with DAT loss, and during the early stages of a diseases with an upregulation of striatal D2/D3R (Brooks, 2010; Niccolini et al., 2014; Zhu et al., 2014).”
Hou, S. S., Yang, J. L., Lee, J. H., Kwon, Y., Calvo-Rodríguez, M., Bao, K., Ahn, S., Kashiwagi, S., Kumar, A. T. N., Bacskai, B. J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01003-7 · Cited by 74 · see citing works
Therapeutic application of exosomes in ischaemic stroke
Li, Y.-F., Tang, Y., & Yang, G. (2021) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000419 · Cited by 73 · see citing works
Recent Advances in Synthetic Methods for Radioiodination
Dubost⧫, E., McErlain, H., Babin, V., Sutherland, A. J., & Cailly, T. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c00644 · Cited by 70 · see citing works
Coordination polymers nanoparticles for bioimaging
Suárez–García, S., Solórzano, R., Novio, F., Alibés, R., Busquè, F., & Ruiz‐Molina, D. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213716 · Cited by 69 · see citing works
Neutral merocyanine dyes: for in vivo NIR fluorescence imaging of amyloid-β plaques
Yan, J., Zhu, J., Zhou, K., Wang, J.-S., Tan, H.-Y., Xu, Z., Chen, S.-B., Lu, Y., Cui, M., & Zhang, L. (2017) · Chemical Communications · doi:10.1039/c7cc05056a · Cited by 69 · see citing works
Wang, X., Iyaswamy, A., Xu, D., Krishnamoorthi, S., Sreenivasmurthy, S. G., Yang, Y., Li, Y., Chen, C., Li, M., Li, H., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c07859 · Cited by 67 · see citing works
Nanotheranostics, a future remedy of neurological disorders
Sharma, M., Dube, T., Chibh, S., Kour, A., Mishra, J., & Panda, J. J. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1562443 · Cited by 66 · see citing works
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 66 · see citing works
Wang, X., Wang, C., Chan, H., Iyaswamy, A., Krishnamoorthi, S. K., Li, M., Li, H., & Wong, M. S. (2020) · Talanta · doi:10.1016/j.talanta.2020.121830 · Cited by 65 · see citing works
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
Tian, M., Civelek, A. C., Carrió, I., Watanabe, Y., Kang, K. W., Murakami, K., Garibotto, V., Prior, J. O., Barthel, H., Zhou, R., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05673-w · Cited by 60 · see citing works
“In recent years, with the development of PET technology and the advent of new tracers, the pathophysiological changes of many major neurodegenerative diseases, including AD, have been explored with the help of PET molecular imaging [16].”
BackgroundMultifunctional Layered Double Hydroxides for Drug Delivery and Imaging
Yu, S., Choi, G., & Choy, J. (2023) · Nanomaterials · doi:10.3390/nano13061102 · Cited by 59 · see citing works
“PET, a molecule-based noninvasive diagnostic imaging method with excellent sensitivity, is particularly suitable for obtaining functional information about slight changes in disease biomarkers in in-vivo systems without any tissue penetration limit [28,104,105].”
BackgroundDevelopment and application of several fluorescent probes in near infrared region
Wang, Y., Yu, H., Zhang, Y., Jia, C., & Ji, M. (2021) · Dyes and Pigments · doi:10.1016/j.dyepig.2021.109284 · Cited by 58 · see citing works
Translational molecular imaging and drug development in Parkinson’s disease
Haider, A., Elghazawy, N. H., Dawoud, A., Gebhard, C., Wichmann, T., Sippl, W., Hoener, M. C., Arenas, E., & Liang, S. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00600-z · Cited by 59 · see citing works
“1C) [38, 39].”
BackgroundLiu, Y., Zhuang, D., Wang, J., Huang, H., Li, R., Wu, C., Deng, Y., Hu, G., & Guo, B. (2022) · The Analyst · doi:10.1039/d2an01327d · Cited by 53 · see citing works
Dyrager, C., Vieira, R. P., Nyström, S., Nilsson, K. P. R., & Storr, T. (2017) · New Journal of Chemistry · doi:10.1039/c6nj01703g · Cited by 53 · see citing works
Arora, H., Ramesh, M., Rajasekhar, K., & Govindaraju, T. (2020) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20190356 · Cited by 53 · see citing works
Sergeev, M. E., Lazari, M., Morgia, F., Collins, J., Javed, M. R., Sergeeva, O., Jones, J., Phelps, M. E., Lee, J. T., Keng, P. Y., et al. (2018) · Communications Chemistry · doi:10.1038/s42004-018-0009-z · Cited by 52 · see citing works
Simon, T., Shellaiah, M., Srinivasadesikan, V., Lin, C.-C., Ko, F., Sun, K. W., & Lin, M. C. (2016) · New Journal of Chemistry · doi:10.1039/c5nj03168k · Cited by 51 · see citing works
In vivo near-infrared fluorescence imaging of amyloid-β plaques with a dicyanoisophorone-based probe
Zhu, J., Zhou, L.-F., Li, Y.-K., Chen, S.-B., Yan, J., & Zhang, L. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.01.017 · Cited by 51 · see citing works
“Along with the development of molecular imaging techniques, in the past decades, the development of Aβ plaques imaging probes for early diagnosis of AD has been of a great interest, including positron emission tomography (PET), single photon emission computed tomography (SPECT)[6], and optical im ging[7].”
Peng, C., Wang, X., Li, Y., Li, H., & Wong, M. S. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00161a · Cited by 51 · see citing works
Strategies for the Molecular Imaging of Amyloid and the Value of a Multimodal Approach
Kaur, A., New, E. J., & Sunde, M. (2020) · ACS Sensors · doi:10.1021/acssensors.0c01101 · Cited by 47 · see citing works
McInnes, L. E., Noor, A., Kysenius, K., Cullinane, C. M., Roselt, P. D., McLean, C., Chiu, F. C. K., Powell, A. K., Crouch, P. J., White, J. M., et al. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b03466 · Cited by 45 · see citing works
Aptamers used for molecular imaging and theranostics - recent developments
Bohrmann, L., Burghardt, T., Haynes, C. A., Saatchi, K., & Häfeli, U. O. (2022) · Theranostics · doi:10.7150/thno.72949 · Cited by 45 · see citing works
“The high sensitivity of nuclear imaging, allows the use of much smaller amounts of imaging agent than for MRI, CT or US [87].”
BackgroundDeep-learning-based methods of attenuation correction for SPECT and PET
Chen, X., & Liu, C. (2022) · Journal of Nuclear Cardiology · doi:10.1007/s12350-022-03007-3 · Cited by 41 · see citing works
“Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) are non-invasive imaging approaches that are widely used for diagnosis and therapy response assessment in cardiology,(1,2) oncology,(3,4) and neurology.(5,6) Photon attenuation is one of the major factors hindering accurate clini…”
MethodLiu, X., Wang, X., Shi, L., Liu, Y., Wang, L., Li, K., Bu, Q., Cen, X., & Yu, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01046 · Cited by 41 · see citing works
Si, G., Zhou, S., Xu, G., Wang, J., Wu, B., & Zhou, S. (2018) · Dyes and Pigments · doi:10.1016/j.dyepig.2018.12.003 · Cited by 36 · see citing works
Wu, J. T., Zhao, Q., Wilson, T. C., Verhoog, S., Lü, L., Gouverneur, V., & Shen, Q. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201813708 · Cited by 35 · see citing works
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
Nwabufo, C. K., & Aigbogun, O. P. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11267-9 · Cited by 35 · see citing works
Revolutionizing Neurology: The Role of Artificial Intelligence in Advancing Diagnosis and Treatment
Kalani, M., & Anjankar, A. (2024) · Cureus · doi:10.7759/cureus.61706 · Cited by 48 · see citing works
“Neuroimaging, including fMRI and PET scans, helps locate the epileptic focus, guiding surgical intervention when necessary [53].”
BackgroundZhu, C., Han, J., Liang, F., Zhu, M., Zhang, G., James, T. D., & Wang, Z. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216002 · Cited by 34 · see citing works
Delivery systems for theranostics in neurodegenerative diseases
Li, Y., Liu, R., Ji, W., Li, Y., Liu, L., & Zhang, X. (2018) · Nano Research · doi:10.1007/s12274-018-2067-z · Cited by 35 · see citing works
“Gamma rays from these radioprobes are collected to localize or quantify specific receptors or binding sites to analyze their cellular distribution and function in the living brain [43].”
BackgroundOno, M., Doi, Y., Watanabe, H., Ihara, M., Ozaki, A., & Saji, H. (2016) · RSC Advances · doi:10.1039/c6ra02710e · Cited by 34 · see citing works
Liu, W., Truillet, C., Flavell, R. R., Brewer, T. F., Evans, M. J., Wilson, D. M., & Chang, C. J. (2016) · Chemical Science · doi:10.1039/c6sc01503d · Cited by 34 · see citing works
Recent Advances in Photo-mediated-Radiofluorination.
Bui, T., & Kim, H.-K. (2021) · Chemistry - An Asian Journal · doi:10.1002/asia.202100399 · Cited by 22 · see citing works
A hemicyanine derivative for near-infrared imaging of β-amyloid plaques in Alzheimer's disease
Yang, H., Fang, S., Tang, Y.-W., Wang, C., Luo, H., Qu, L., Zhao, J., Shi, C., Yin, F., Wang, X., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.005 · Cited by 32 · see citing works
Ma, X., Wang, Y., Hua, J., Xu, C., Yang, T., Yuan, J., Chen, G., Guo, Z., & Wang, X. (2019) · Science China Chemistry · doi:10.1007/s11426-019-9594-y · Cited by 30 · see citing works
Design of a Coumarin-Based Fluorescent Probe for Efficient In Vivo Imaging of Amyloid-β Plaques
Cao, Y., Liu, X., Zhang, J., Liu, Z., Fu, Y., Zhang, D., Zheng, M., Zhang, H., & Xu, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00468 · Cited by 29 · see citing works
Zheng, J., Wang, L., Lin, J., Xiao, J., & Liang, S. H. (2015) · Angewandte Chemie · doi:10.1002/ange.201505446 · Cited by 28 · see citing works
Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective
Kręcisz, P., Stefańska, K., Studziński, J., Pitucha, M., Czylkowska, A., & Szymański, P. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02885 · Cited by 27 · see citing works
Hong, X., Liu, Y., Lü, L., & Shen, Q. (2020) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202000206 · Cited by 27 · see citing works
Liang, S. H., Holland, J. P., Stephenson, N. A., Kassenbrock, A. R., Rotstein, B. H., Daignault, C. P., Lewis, R., Collier, L., Hooker, J. M., & Vasdev, N. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00055 · Cited by 27 · see citing works
“dementias.[1] Several PET radiopharmaceuticals have been developed to interrogate Aβ plaques,”
BackgroundLin, Y., Sun, L., Zeng, F., & Wu, S. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201904675 · Cited by 25 · see citing works
Development of BODIPY-based fluorescent probes for imaging Aβ aggregates and lipid droplet viscosity
Li, K., Wang, Y., Li, Y., Shi, W., & Yan, J. (2024) · Talanta · doi:10.1016/j.talanta.2024.126362 · Cited by 24 · see citing works
Facile Preparation of Gold-Decorated Fe3O4 Nanoparticles for CT and MR Dual-Modal Imaging
Cai, J., Miao, Y., Li, L., & Fan, H. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124049 · Cited by 24 · see citing works
“With the development of clinical imaging technology, multimodal imaging has become an important research area in recent decades because of its ability to provide more sufficient and accurate imaging information than individual modalities [3], such as Positron Emission Tomography (PET)/ Computed Tomography (CT) [4], PE…”
BackgroundPET‐Based Dual‐Modal Probes for In Vivo Imaging
Zhao, R., Lan, D., Xia, B., Dong, M., Mu, J., & Zhao, Y. (2025) · Small · doi:10.1002/smll.202409713 · Cited by 22 · see citing works
6-Methoxy-indanone derivatives as potential probes for β-amyloid plaques in Alzheimer's disease
Nan, D., Gan, C., Wang, C.-W., Qiao, J., Wang, X.-M., & Zhou, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.069 · Cited by 21 · see citing works
An imaging review of the hippocampus and its common pathologies
Lang, M., Colby, S., Ashby‐Padial, C., Bapna, M., Jaimes, C. E., Rincon, S., & Buch, K. A. (2023) · Journal of Neuroimaging · doi:10.1111/jon.13165 · Cited by 20 · see citing works
“41,42 FDG-PET has higheraccuracyandprovidessuperiorimageresolutionthanSPECTfor diagnosis of hippocampal-related conditions.”
BackgroundWang, P., Yu, L., Gong, J., Xiong, J., Zi, S., Xie, H., Zhang, F., Mao, Z., Liu, Z., & Kim, J. S. (2022) · Angewandte Chemie · doi:10.1002/ange.202206894 · Cited by 20 · see citing works
Wang, W., Liu, W., Xu, S., Dong, X., & Sun, Y. P. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00295 · Cited by 20 · see citing works
Radiolabeled peptide probe for tumor imaging
Yan, Y.-Q., Wang, H., & Zhao, Y. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.02.016 · Cited by 19 · see citing works
Compounds for imaging amyloid-β deposits in an Alzheimer’s brain: a patent review
Tu, P.-Y., Fu, H.-L., & Cui, M. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1007953 · Cited by 19 · see citing works
“Massive research has demonstrated that PET is a powerful tool in the early diagnosis of AD [11].”
MethodFu, H., Peng, C., Liang, Z., Dai, J., Liu, B., & Cui, M. (2016) · Chemical Communications · doi:10.1039/c6cc06995a · Cited by 19 · see citing works
Cigdem, O., Yilmaz, A., Beheshti, I., & Demirel, H. (2018) · Signal Processing and Communications Applications Conference (SIU) · doi:10.1109/siu.2018.8404697 · Cited by 18 · see citing works
“In literature, there are different available neuroimaging modalities for detection of PD, namely magnetic resonance imaging (MRI) [3], positron emission tomography (PET) [7], single photon emission computed tomography (SPECT) [7], diffusion tensor imagiging (DTI) [8], and transcranial Doppler [TCD].”
BackgroundFang, Y., Wang, Q., Xiang, C., Liu, G., & Li, J. (2023) · Biosensors · doi:10.3390/bios13060610 · Cited by 17 · see citing works
“Currently, the common clinical diagnostic tools for AD rely on clinical symptoms combined with imaging, including computed tomography, magnetic resonance imaging, and positron emission tomography [7,8].”
BackgroundMapping of Amyloid-β Aggregates In Vivo by a Fluorescent Probe with Dual Recognition Moieties
Liang, F., Ma, L., Zhang, G., Han, J., Zhu, M., Zhu, C., Jin, Y., & Wang, Z. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06385 · Cited by 17 · see citing works
Chen, J., Wang, X., Liu, X., Shi, L., Yu, X., Cen, X., & Li, K. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01619 · Cited by 16 · see citing works
Krüll, J., & Heinrich, M. R. (2018) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201800494 · Cited by 10 · see citing works
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease
Zhou, C., Zeng, F., Yang, H., Liang, Z., Xu, G., Li, X., Liu, X., & Yang, J. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06690-1 · Cited by 14 · see citing works
“So far, numerous technologies have been applied for early diagnosis of AD, including magnetic resonance imaging (MRI) [5, 6], positron emission tomography (PET) [7–9], single-photon emission computed tomography (SPECT) [8], and optical imaging [10, 11].”
Photocatalyzed ditrifluoromethylthiolation of alkenes with CF3SO2Na
Chen, F., Jiang, L., Hu, C., Liu, J., & Yi, W. (2023) · Science China Chemistry · doi:10.1007/s11426-023-1781-6 · Cited by 14 · see citing works
Mallesh, R., Khan, J., Gharai, P. K., Ghosh, S., Garg, S., Arshi, M. U., & Ghosh, S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00787 · Cited by 14 · see citing works
Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-β Plaques
Hayne, D. J., White, J. M., McLean, C., Villemagne, V. L., Barnham, K. J., & Donnelly, P. S. (2016) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6b00972 · Cited by 14 · see citing works
Metal complexes for multimodal imaging of misfolded protein-related diseases
Lacerda, S., Morfin, J., Geraldes, C. F. G. C., & Tóth, É. (2017) · Dalton Transactions · doi:10.1039/c7dt02371e · Cited by 14 · see citing works
Fluorescence microscopic platforms imaging mitochondrial abnormalities in neurodegenerative diseases
Wang, Y., Wang, P., & Li, C. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114841 · Cited by 13 · see citing works
AI in SPECT Imaging: Opportunities and Challenges
Yang, F., Lei, B., Zhou, Z., Song, T.-A., Balaji, V., & Dutta, J. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.03.005 · Cited by 13 · see citing works
Pan, M., Mukherjee, M. T., Patel, H., Patel, B. A., Constantinescu, C. C., Mirbolooki, M., Liang, C., & Mukherjee, J. (2016) · Synapse · doi:10.1002/syn.21893 · Cited by 14 · see citing works
“1; 2) was the first fluorine-18 agent approved for clinical use in AD (Stephenson et al., 2007; Zhang et al., 2005; Zhu et al., 2014).”
BackgroundMapping neuroreceptors with metal-labeled radiopharmaceuticals
Chaturvedi, S., Kaul, A., Hazari, P. P., & Mishra, A. K. (2017) · MedChemComm · doi:10.1039/c6md00610h · Cited by 13 · see citing works
Melo, L., Silva, A. M. S., & Albuquerque, H. M. T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117874 · Cited by 12 · see citing works
Vatsadze, S. Z., Eremina, O. E., Veselova, I. A., Kalmykov, S. N., & Nenajdenko, V. G. (2017) · Russian Chemical Reviews · doi:10.1070/rcr4752 · Cited by 12 · see citing works
Fletcher, S. P., Noor, A., Hickey, J. L., McLean, C., White, J. M., & Donnelly, P. S. (2018) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-018-1590-4 · Cited by 12 · see citing works
A fluorescent probe for concurrent detection of cysteine, homocysteine, and superoxide anion
Li, Y., Yu, T., Wang, Z., Wang, J., Tang, Y., Zhang, Y., Li, H., Zhou, H., Yin, P., & Yao, S. (2025) · Science Advances · doi:10.1126/sciadv.adx6659 · Cited by 11 · see citing works
“Epilepsy and liver injury are particularly vulnerable to oxidative stress due to their high metabolic activity and dependence on redox-sensitive signaling pathways ( 9 – 11 ).”
Li, C., Jia, H., Zhao, W., Wu, R., Zhou, X., Wei, X., Xue, G., Shen, Z., & Xue, C. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202405780 · Cited by 11 · see citing works
Bera, T., Mondal, A., Kar, S., Mukherjee, A., Banerjee, S., & Guha, S. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb01337a · Cited by 11 · see citing works
McInnes, L. E., Noor, A., Roselt, P. D., McLean, C., White, J. M., & Donnelly, P. S. (2019) · Australian Journal of Chemistry · doi:10.1071/ch19311 · Cited by 11 · see citing works
Kamya, E., Lu, Z., Cao, Y., & Pei, R. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01903e · Cited by 10 · see citing works
- Authors
- Zhu, L., Ploessl, K., & Kung, H. F.
- Affiliations
- Capital Medical University (CN)
- Departments of Radiology
- University of Pennsylvania (US)
- Corresponding author
- Zhu, Lin
- Venue
- Chem. Soc. Rev.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2014
- Volume
- 43
- Issue
- 19
- Pages
- 6683-6691
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- PMC
- PMC4159420
- OpenAlex
- W2082184462
- Cited by
- 185
- References
- 48
- Citations by year
- 2026: 11 · 2025: 24 · 2024: 22 · 2023: 19 · 2022: 21 · 2021: 10 · 2020: 12 · 2019: 11 · 2018: 18 · 2017: 13 · 2016: 15 · 2015: 9
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (R01AG022559, AG022559)
- National Cancer Institute (CA-164490, R01CA164490)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081342, DK081342)
- National Institute of Biomedical Imaging and Bioengineering (R01EB000360)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- PET imaging agents, SPECT radiotracer, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, radiopharmaceutical synthesis, neuroimaging, drug target identification, preclinical drug screening
- MeSH terms
- Alzheimer Disease, Contrast Media, Humans, Parkinson Disease, Radiography, Tomography, Emission-Computed, Single-Photon, Amyloid beta-Peptides, Radiopharmaceuticals, Neurodegenerative Diseases, Positron-Emission Tomography, Dopamine Plasma Membrane Transport Proteins, Vesicular Monoamine Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
